title: Emerging high-throughput drug target validation technologies.
abstract: Identifying the right target for drug development is a critical bottleneck in the pharmaceutical and biotech industries. The genomics revolution has shifted the problem from a scarcity of targets to a surplus of putative drug targets. As the validity of a target cannot be simply inferred from correlative data, the key is confirmation of the causative role of a gene product in a particular disease. It should therefore be recognized that an effective therapeutic strategy requires an appropriate target validation technology to verify the right target.
authors.affiliation: Xerion Pharmaceuticals, Fraunhoferstr. 9, 82152 Martinsried, Germany. l.ilag@xerion-pharma.com
authors.forename: Leodevico L
authors.initials: LL
authors.lastname: Ilag
authors.forename: Jocelyn H
authors.initials: JH
authors.lastname: Ng
authors.forename: Gerald
authors.initials: G
authors.lastname: Beste
authors.forename: Stefan W
authors.initials: SW
authors.lastname: Henning
mesh_terms: D001709:Biotechnology / Q000639:trends; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends*; D004345:Drug Industry / Q000639:trends; D023281:Genomics; D010641:Phenotype; D011506:Proteins / Q000737:chemistry / Q000235:genetics; D015203:Reproducibility of Results; D012371:Robotics
chemical_list: D011506:Proteins